Regulatory effects of miR-28 on osteogenic differentiation of human bone marrow mesenchymal stem cells

Min Wang1, Tianming Dai1, Qingqi Meng1

  • 1Department of Orthopedics, Guangzhou Red Cross Hospital, Jinan University, Guangzhou Guangdong Province, China.

Bioengineered
|January 3, 2022
PubMed

Insights

MicroRNA-28 (miR-28) promotes bone formation by targeting STAT1 in human mesenchymal stem cells. Increased miR-28 expression enhances osteogenic differentiation, crucial for bone development and repair.

Area of Science:

  • Molecular Biology
  • Stem Cell Biology
  • Regenerative Medicine

Background:

  • Mesenchymal stem cells (MSCs) are critical for bone regeneration.
  • MicroRNAs (miRNAs) play regulatory roles in stem cell differentiation.
  • The specific role of miR-28 in osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMMSCs) requires elucidation.

Purpose of the Study:

  • To investigate the regulatory function of miR-28 in the osteogenic differentiation of hBMMSCs.
  • To identify the downstream target of miR-28 involved in this process.

Main Methods:

  • hBMMSCs were isolated, cultured, and induced for osteogenic differentiation.
  • miRNA expression profiling was performed using gene microarrays and validated by RT-PCR.
  • TargetScan, dual-luciferase reporter assays, transfection with miR-28 mimics/STAT1 siRNA, Western blotting, and RT-PCR were used to confirm interactions and effects.

Main Results:

  • miR-28 expression significantly increased during hBMMSC osteogenic differentiation.
  • miR-28 directly targets the 3'-untranslated region (3'UTR) of signal transducer and activator of transcription 1 (STAT1) mRNA, inhibiting its expression.
  • Overexpression of miR-28 or inhibition of STAT1 promoted alkaline phosphatase (AKP) activity and Runt-related transcription factor 2 (RUNX2) expression, key markers of osteogenesis.

Conclusions:

  • miR-28 acts as a positive regulator of hBMMSC osteogenic differentiation.
  • The mechanism involves direct inhibition of STAT1 expression.
  • miR-28 holds potential as a therapeutic target for enhancing bone formation.